

Robust and sensitive detection of gene fusions using high-throughput SMART-Seq chemistry on the ICELL8 cx system



Rachel Fish, Michael J. Young, Lyndon Liu, Sherry Wei, Karthikeyan Swaminathan, Magnolia Bostick, Nidhanjali Bansal, Necip Mehmet, Suvarna Gandlur, and Andrew Farmer* Takara Bio USA, Inc., Mountain View, CA, USA; *Corresponding author: andrew_farmer@takarabio.com

Abstract

Isolating single cells at high-throughput levels and obtaining their full-length transcript information has become critical to the scientific community to generate rich single-cell datasets. We automated SMART-Seq® chemistry on the ICELL8® cx Single-Cell System to address this need and show this workflow provides useful information that end-capture technologies cannot. We present performance data showing that capturing junction and spanning reads with this automated, full-length mRNA-seq method enables confident and robust identification of gene fusions in a breast cancer tumor cell line.

1 SMART-Seq ICELL8 application kit workflow




Figure 1. ICELL8 instrument and SMART-Seq ICELL8 application kit workflow: full-length scRNA-seq on the ICELL8 system. The ICELL8 system is an open-platform automated system that provides unparalleled sensitivity and flexibility. The full-length application kit's 8-hr protocol requires five ICELL8 dispensing steps. Cultured cells are dispensed into the wells of a blank, 5,184-well ICELL8 chip at an average of 1 cell/well (Step 1). Built-in cell-selection software is used to identify wells with single cells. Cell lysis is followed by cDNA synthesis and amplification (Step 2). Full-length cDNA is tagmented with Illumina® Nextera® TDE1 and amplified with Illumina-specific indexed adapters added in a 72 x 72 grid-like fashion to generate uniquely indexed cDNA libraries in each well (Steps 3-5). The final libraries are pooled, further amplified, and purified prior to sequencing.

Methods and references

For experiments performed on the ICELL8 system: Cells (Figures 2 & 3: K-562 cells [ATCC CCL-243]; Figure 4: HCC2157 [ATCC CRL-2340] and control cells) were dispensed across an ICELL8 chip together with 48 negative-control wells (containing only PBS) and 48 positive-control wells (containing 10 pg K-562 RNA). The ICELL8 system's cell-selection software was used to identify single-cell candidate wells. For Figure 2 experiments, using IDT's Target Capture Probe Design Tool, 120-nt probes were designed to include the junction of the *BCR-ABL1* fusion as well as from 1 kb upstream (in *BCR*) to 1 kb downstream (in *ABL1*) of the fusion tiled at 1X density. Following IDT's xGen Lockdown protocol, probes were used to capture target genes from 500 ng of a SMART-Seq library generated from 1,512 K-562 cells. For Figure 3, 1,000 single-cell wells of K-562 were selected, and for Figure 4, 1,122 single-cell wells of HCC2157 were selected. These single-cell wells, together with the positive and negative controls, were then processed according to the SMART-Seq ICELL8 application kit protocol using 12 cycles of PCR during the RT-PCR step. The resulting libraries were sequenced together on an Illumina NextSeq® instrument with paired-end 2 x 75-bp reads. HCC2157 cells had a mean of 284,000 reads per cell. Demultiplexing was performed using mapppa™ software from Takara Bio.

For experiments performed on the 10x system: Single-cell capture and library preparation were performed by MedGenome using Chromium Single Cell 3' gene expression v3 chemistry. For Figure 3, ~1,500 K-562 cells were captured and processed, and for Figure 4, HCC2157 cells were captured and processed. The resulting libraries were sequenced on an Illumina NovaSeq™ instrument with PE100 chemistry. The HCC2157 cells had a mean of 50,000 reads per cell, according to the manufacturer's recommendation. Demultiplexing was performed using Cell Ranger software.

References

Haas, B. J. *et al.* STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq. *bioRxiv* 120295 (2017).

Broad Institute. DepMap: The Cancer Dependency Map Project at Broad Institute. (2019). at <https://depmap.org/portal/>

Conclusions

Takara Bio's SMART-Seq ICELL8 application kit workflow:

- Captures both junction and spanning reads to confidently identify gene fusions
- Identifies fusions across the full transcript length
- Provides greater fusion identification at a lower sequencing depth
- Provides full-length sequence information, high sensitivity, and high reproducibility

2 Improved fusion detection with targeted enrichment of SMART-Seq libraries




Figure 2. Targeted enrichment of *BCR* and *ABL1* genes from a SMART-Seq library improves identification of cells containing the *BCR-ABL1* fusion. Out of 1,512 cells, only 40 were determined to express transcripts containing the *BCR-ABL1* fusion even at a sequencing depth of greater than 1.6M reads with the SMART-Seq workflow. In contrast, targeted enrichment of *BCR* and *ABL1* from the same library determined that 264 cells expressed the *BCR-ABL1* fusion at a depth of only 582K reads.

3 Full-length chemistry detects more fusions




Figure 3. The SMART-Seq ICELL8 workflow detects a higher percentage of cells with fusions. Panel A. In this proof-of-concept experiment using K-562 cells, fusions were counted if they were reported by "DepMap: The Cancer Dependency Map Consortium" or supported in the literature. This led to a total of eight fusions identified across the two platforms. The SMART-Seq ICELL8 workflow detected fusions in 46% of the cell population, while the 10x 3' DE workflow detected fusions in only 16% of the cell population. The ICELL8 workflow was able to identify cells with up to four unique fusions, while the 10x workflow could not identify three or four fusions in any cell. Panel B. The distribution of reads is shown for cells in which at least one fusion was identified. The SMART-Seq ICELL8 workflow detected up to four fusions per cell at a lower read depth than the 10x 3' DE workflow, which was not able to detect more than two fusions per cell.

4 Full-length chemistry detects junction and spanning reads, improving fusion identification




Figure 4. The SMART-Seq ICELL8 workflow uniquely detects both junction and spanning reads, improving confidence in fusion detection. HCC2157 is a breast cancer cell line. A total of 18 fusions were detected in the HCC2157 line and confirmed to be reported in "DepMap: The Cancer Dependency Map Consortium." In this figure, fusions identified in at least 1% of the cells on either platform are shown (with the exception of those examined in more detail in Figure 5). The 10x 3' DE workflow ("10x") is only able to detect junction reads, whereas the SMART-Seq ICELL8 workflow ("ICELL8") detects a combination of junction and spanning reads. This ICELL8 advantage, made possible by full-length coverage, leads to a higher sensitivity of fusion identification, which is supported by the higher percentage of cells detected with fusion events.

5 Full-length chemistry provides higher confidence in fusion discovery




Figure 5. A deeper look into selected HCC2157 fusions. Panel A. In the HCC2157 cells, there were four fusions that stood out (from the experiment performed in Figure 4). For the *ASCC1-MICU1* and *RANBP1-TANGO2* fusions, the detection rate using the SMART-Seq ICELL8 workflow ("ICELL8") is dramatically higher than the 10x 3' DE workflow ("10x"). Panel B. Further investigation into the *ASCC1-MICU1* fusion showed that there is a long exon (>1 kb) at the 3' end of *MICU1*, which likely leads to a low representation of the junction with 10x. This model is depicted (not to scale) in the top-right schematic. Data suggest a similar scenario for the *RANBP1-TANGO2* fusion. *SMYD3-ZNF695* and *AXIN1-LMF1* (the latter depicted in the bottom-right schematic; Panel C) have shorter exons (<200 bp) at the 3' end, which likely allows junction detection with 10x. Even so, ICELL8 system's full-length coverage provides more information and higher confidence overall due to the ability to obtain both junction and spanning reads.

Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)11.3904.6880 • Japan: +81.(0)77.565.8999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2020 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliates in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com

800.662.2566
Visit us at [takarabio.com](https://www.takarabio.com)

Clontech Takara cellartis